Thus, various studies have evaluated whether the prognosis of patients with breast cancer and other malignancies can be predicted using systemic inflammatory markers, such as lactate dehydrogenase (LDH) [10], C-reactive protein (CRP) [11, 12], albumin [13], the platelet-to-lymphocyte ratio (PLR) [14], absolute lymphocyte count (ALC) [15, 16], and the lymphocyte-to-monocyte ratio (LMR) [17–19]. The gene discussed is CRP; the disease is breast carcinoma.